Drugs / ARV-766
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05067140 | Sep 2021 → May 2027 expected | metastatic prostate carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-02-27 | Arvinas Inc. | Results Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update arvinas.com ↗
New interim data from Phase 1/2 trial with ARV-766 showed a broader efficacy profile and superior tolerability versus bavdegalutamide in the clinical setting, with a potentially differentiated profile against other AR-directed therapies. |
| 2023-10-22 | Arvinas Inc. | Results Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC arvinas.com ↗
New data from the ongoing Phase 1/2 clinical trial of ARV-766 continues to show robust efficacy in tumors with all LBD mutations (41% PSA 50 ) and in patients with tumors harboring AR L702H mutations (50% PSA 50 ). |
| 2023-08-08 | Arvinas Inc. | Results Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update arvinas.com ↗
Interim data from Phase 1/2 dose escalation and expansion trial with ARV-766 shows promising signals of efficacy in late-line novel hormonal therapy pre-treated mCRPC |
| 2023-06-08 | Arvinas Inc. | Results Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations arvinas.com ↗
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced promising interim data from the Company’s Phase 1/2 dose escalation and expansion trial of ARV-766 in men with metastatic castration-resistant prostate cancer (mCRPC). |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARV-766 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05067140 ↗ |
| Route | Oral | “Part B: Oral tablet(s) once daily in 28 day cycles.” NCT05067140 ↗ |